Acute PTSD refers to the early phase of post-traumatic stress disorder, with symptoms persisting >1 month after trauma exposure. This is distinct from acute stress disorder (ASD), which occurs 3 days to 1 month post-trauma. [1] Approximately half of ASD patients progress to PTSD, though most PTSD patients were never formally diagnosed with ASD. [2] Lifetime prevalence is ~6%, with women affected twice as often as men. [1-2]
1. History
- Nature of trauma: Direct experience, witnessing, learning of event involving close family/friend, or occupational exposure to aversive details (e.g., first responders) [1]
- Symptom characterization: Assess across four DSM-5-TR clusters — intrusion, avoidance, negative cognition/mood, and arousal/reactivity [2]
- Timing: When did the trauma occur? When did symptoms begin? Symptoms must persist >1 month for PTSD diagnosis (vs. ASD if <1 month) [1]
- Intrusion symptoms: Flashbacks, nightmares, intrusive memories — frequency, triggers, intensity
- Avoidance: Internal (thoughts, feelings) and external (places, people, activities) avoidance behaviors
- Negative cognition/mood: Persistent blame, guilt, shame, emotional numbing, loss of interest, detachment
- Arousal: Sleep disturbance, irritability/anger outbursts, hypervigilance, exaggerated startle, concentration difficulty, reckless/self-destructive behavior [1][3]
- Important negatives: Somatic complaints (GI distress, musculoskeletal pain) are common and may be the presenting complaint [2]
2. Alarm Features
- Suicidal ideation or intent — PTSD is a strong independent risk factor for suicidal ideation and completion; assess at every encounter [2]
- Homicidal ideation or aggressive behavior, especially in externalizing presentations
- Active psychotic symptoms (command hallucinations vs. flashbacks — distinguish carefully) [1]
- Severe dissociative episodes (depersonalization, derealization, dissociative amnesia) impairing safety [1]
- Acute intoxication or withdrawal — substance use is highly comorbid and increases risk
- Self-destructive or reckless behavior (e.g., driving dangerously, substance bingeing)
- Inability to care for self or maintain basic functioning
- Concurrent TBI — overlapping symptoms require careful differentiation; persistent disorientation/confusion favors TBI [1]
3. Medications
First-line pharmacotherapy (when psychotherapy is unavailable, refused, or insufficient):
- Sertraline 25–200 mg/day (FDA-approved for PTSD) [4-5]
- Paroxetine 20–50 mg/day (FDA-approved for PTSD) [4-5]
- Venlafaxine 75–225 mg/day [4-5]
Adjunctive/second-line
- Prazosin 1–15 mg at bedtime for trauma-related nightmares (mixed evidence; improves nightmares but not overall PTSD symptoms) [2][6]
- Mirtazapine, amitriptyline, imipramine — reserved for treatment-refractory cases [2][7]
Contraindicated/recommended against
- Benzodiazepines — strongly recommended against by VA/DoD 2023 CPG; associated with misuse, decreased effectiveness of psychotherapy, adverse cognitive effects, and no evidence of benefit [3][5]
- Cannabis/cannabis-derived products — recommended against due to lack of RCT evidence and potential harms [5]
- Divalproex, guanfacine, ketamine, risperidone, tiagabine — recommended against for overall PTSD treatment [5]
Cautions
- Paroxetine: higher discontinuation rates due to tolerability (sexual dysfunction, withdrawal syndrome) [4]
- Venlafaxine: monitor blood pressure; discontinuation syndrome [4]
- Titrate SSRIs/SNRIs to maximum tolerated dose; reassess after 8–12 weeks before switching [2]
4. Diet
- No specific dietary interventions are evidence-based for PTSD
- Caffeine and stimulants may worsen hyperarousal, insomnia, and anxiety — counsel on moderation
- Alcohol: Frequently used as self-medication; worsens sleep architecture, increases impulsivity, and interferes with treatment response
- Encourage regular meals and adequate hydration, as disrupted routines are common
5. Review of Systems
- Psychiatric: Depression (most common comorbidity), anxiety, panic attacks, substance use, suicidal ideation
- Sleep: Insomnia, nightmares, night sweats, sleep-disordered breathing (screen for OSA — high prevalence in PTSD) [2]
- Neurologic: Headaches, dizziness, concentration/memory difficulties, dissociative episodes
- GI: Nausea, abdominal pain, IBS-type symptoms (common somatic presentation) [2]
- Cardiovascular: Palpitations, chest tightness (hyperarousal-related)
- Musculoskeletal: Chronic pain, tension, myalgias [2]
- Reproductive: Sexual dysfunction, decreased libido
6. Collateral History and Family History
- Collateral: Corroborate behavioral changes — irritability, withdrawal, aggression, substance use, functional decline at work/home
- Family history: Psychiatric disorders (depression, anxiety, PTSD, substance use) increase susceptibility [1]
- Social context: Current safety (ongoing domestic violence, homelessness), social support network (protective factor), employment status, legal involvement
- Military/occupational history: Combat exposure, first responder duties, prior deployments [1]
7. Risk Factors
- Female sex (OR ~2.2–2.3 for PTSD) [1][8]
- Interpersonal violence (sexual assault, physical assault, combat) — highest conditional probability of PTSD [9]
- Cumulative trauma exposure — dose-response relationship [9]
- Prior psychiatric history (depression, anxiety, prior PTSD) [1]
- Childhood adversity (abuse, neglect, family dysfunction) [1][9]
- Lower socioeconomic status, lower education, minority status [1][10]
- Lack of social support post-trauma [8][10]
- Peritraumatic dissociation and perceived life threat [10]
- TBI co-occurrence [1]
- Younger age, LGBTQIA+ identity (higher trauma exposure) [2]
8. Differential Diagnosis
- Acute stress disorder (ASD): Same symptom clusters but duration 3 days to 1 month; diagnosis changes to PTSD if symptoms persist >1 month [1-2]
- Major depressive disorder: May co-occur; negative cognition/mood overlap, but lacks intrusion/re-experiencing symptoms [1]
- Generalized anxiety disorder: Chronic worry without trauma-linked intrusions or avoidance
- Panic disorder: Spontaneous panic attacks without trauma-specific triggers [1]
- Adjustment disorder: Stressor does not meet Criterion A severity; symptoms are less specific [1]
- Traumatic brain injury: Overlapping symptoms (irritability, concentration difficulty); persistent disorientation/confusion favors TBI; re-experiencing and avoidance favor PTSD [1]
- Substance use disorders: Intoxication/withdrawal can mimic arousal and mood symptoms
- Dissociative disorders: Severe dissociation without other PTSD features [1]
- Brief psychotic disorder: Distinguish flashbacks from true hallucinations — flashbacks are trauma-related and occur without other psychotic features [1]
- OCD: Intrusive thoughts are obsessional, not trauma-linked; compulsions present [1]
9. Past Medical History
- Prior traumatic exposures and prior PTSD episodes
- Pre-existing psychiatric diagnoses (depression, anxiety, substance use disorders, personality disorders)
- History of childhood trauma or adverse childhood experiences (ACEs)
- Prior suicide attempts
- TBI history
- Chronic pain conditions
- Surgical history (especially trauma-related surgeries)
- Current and past substance use (alcohol, opioids, cannabis, stimulants)
10. Physical Exam
- Vital signs: Tachycardia, elevated blood pressure, tachypnea (sympathetic hyperarousal) [9]
- General: Hypervigilance (scanning the room), exaggerated startle response, psychomotor agitation or flat/constricted affect
- HEENT: Signs of substance use (pupil changes, nasal septal changes), evidence of trauma/injury
- Skin: Self-harm scars (cutting, burning), signs of physical abuse
- Neurologic: Assess orientation, concentration, memory; screen for TBI signs (if applicable)
- MSK: Tension, guarding, chronic pain complaints
- Mental status exam: Mood (anxious, dysphoric, irritable), affect (restricted, labile, hyperreactive), thought content (intrusive memories, guilt, suicidal/homicidal ideation), perceptual disturbances (flashbacks vs. hallucinations), insight and judgment
11. Lab Studies
- No specific labs diagnose PTSD — labs are used to rule out medical mimics and assess comorbidities
- CBC, CMP: Baseline; rule out metabolic/endocrine causes of symptoms
- TSH: Thyroid dysfunction can mimic anxiety, mood changes, sleep disturbance
- Urine drug screen: Assess for concurrent substance use (high comorbidity)
- Blood alcohol level: If acute intoxication suspected
- Hepatic panel: If substance use or medication initiation planned
- Cortisol levels: Not routinely indicated clinically (low cortisol has been associated with PTSD risk in research settings) [9]
12. Imaging
- Not routinely indicated for PTSD diagnosis
- CT head: If concern for concurrent TBI (especially in trauma patients with altered mental status, focal deficits, or persistent disorientation) [1]
- MRI brain: Consider if atypical neurologic findings or concern for structural pathology
- Neuroimaging findings in PTSD (reduced hippocampal volume, amygdala hyperactivity) are research tools, not clinical diagnostics
13. Special Tests
Screening tools
- PC-PTSD-5 (Primary Care PTSD Screen): 5-item screener; cutoff ≥3 for sensitivity, ≥4 for optimal efficiency; validated in civilian and veteran populations [5][11]
- PCL-5 (PTSD Checklist for DSM-5): 20-item self-report; score ≥33 suggests probable PTSD; useful for diagnosis and severity monitoring [2][12]
Diagnostic gold standard
For hospitalized trauma patients
- Injured Trauma Survivor Screen (ITSS)[12]
Other assessments
- Columbia Suicide Severity Rating Scale (C-SSRS) or equivalent for suicide risk
- PHQ-9 for comorbid depression screening
- AUDIT-C for alcohol use screening
14. ECG
- Not routinely required for PTSD diagnosis
- Obtain if:
- Initiating medications with cardiac effects (e.g., TCAs — QTc prolongation)
- Patient presents with palpitations, chest pain, or syncope
- Concern for stimulant or substance use
- Sinus tachycardia is the most common finding during acute hyperarousal episodes
15. Assessment
Clinical summary: Acute PTSD is a clinical diagnosis based on DSM-5-TR criteria requiring ≥1 month of symptoms across four clusters (intrusion, avoidance, negative cognition/mood, arousal/reactivity) following a Criterion A traumatic event, with clinically significant distress or functional impairment. [1-2]
Severity stratification: Use PCL-5 scores for severity grading and longitudinal monitoring. [2] Two-thirds of patients report moderate to severe symptoms. [2]
Typical vs. atypical presentations
- Typical: Nightmares, flashbacks, hypervigilance, avoidance of trauma reminders
- Atypical: Predominantly somatic complaints (GI, pain), dissociative subtype (depersonalization/derealization), externalizing (anger, aggression, recklessness), delayed onset (~25% of cases, especially military) [1][9]
Complications: Comorbid depression (most common), substance use disorders, suicidality, cardiovascular disease, chronic pain, functional impairment, relationship disruption [2][9]
16. Treatment Plan
Initial stabilization (ED/acute setting)
- Ensure physical safety; assess and address suicidality
- Normalize acute stress reactions; provide psychoeducation
- Avoid debriefing-style interventions (no evidence of benefit; may be harmful)
- Avoid benzodiazepines [5]
First-line treatment — Psychotherapy (strongly recommended over pharmacotherapy): [5][13]
- Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), or Eye Movement Desensitization and Reprocessing (EMDR) — all strongly recommended by VA/DoD 2023 CPG [5]
- Typically 6–12 weekly sessions, 60–90 minutes each [2]
- Written Exposure Therapy (WET): Briefer alternative feasible in primary care [14]
- For ASD (<1 month): Trauma-focused CBT reduces risk of progression to PTSD [2]
Pharmacotherapy (when psychotherapy unavailable, refused, or insufficient): [2][5]
- Sertraline 25 mg → titrate to 50–200 mg/day
- Paroxetine 20 mg → titrate to 20–50 mg/day
- Venlafaxine 37.5 mg → titrate to 75–225 mg/day
- Reassess at 8–12 weeks at maximum tolerated dose before switching [2]
- For SSRI non-responders: switching to venlafaxine may be more effective than augmentation [14]
Sleep disturbance
- CBT for insomnia (CBT-I) recommended before sedative-hypnotics [2]
- Prazosin 1 mg at bedtime, titrate to 1–15 mg for trauma-related nightmares [2][15]
- Screen for and treat OSA [2]
Comorbidities: Treat depression, substance use, and other psychiatric conditions concurrently — do not delay PTSD treatment [2]
The following figure outlines a clinical algorithm for PTSD evaluation and management:
17. Disposition
Admission criteria
- Active suicidal or homicidal ideation with plan/intent
- Severe psychotic symptoms or dissociative episodes impairing safety
- Inability to care for self or maintain safety
- Acute intoxication/withdrawal requiring medical management
- Need for inpatient psychiatric stabilization
Discharge criteria
- No imminent danger to self or others
- Adequate social support and safe living environment
- Able to contract for safety (with caveats regarding reliability)
- Outpatient follow-up arranged
Observation indications
- Passive suicidal ideation without plan, requiring further risk stratification
- Severe agitation requiring monitoring after medication administration
Specialist consultation triggers
- Psychiatry: Treatment-refractory symptoms, complex comorbidities, medication management
- Psychology/behavioral health: Trauma-focused psychotherapy referral
- Social work: Safety planning, housing, domestic violence resources
- Neurology/neurosurgery: If concurrent TBI suspected
18. Follow Up / Return Precautions
Follow-up timing
- Primary care or behavioral health within 1–2 weeks of ED visit or initial diagnosis
- Pharmacotherapy: Reassess in 2–4 weeks after initiation for tolerability and early response; titrate as needed
- Psychotherapy: Weekly to biweekly sessions for 6–12 weeks [2]
- PCL-5 at each visit to monitor symptom trajectory [5]
Symptoms requiring immediate reassessment
- New or worsening suicidal ideation
- Homicidal ideation or violent behavior
- Severe dissociative episodes or psychotic symptoms
- Inability to function (not eating, not sleeping, unable to work)
- Worsening substance use
Patient counseling points
- PTSD is a treatable condition; most patients improve with evidence-based treatment [13]
- Symptoms may fluctuate — worsening does not mean treatment failure
- Avoid alcohol and substance use as coping mechanisms
- Maintain routines (sleep hygiene, physical activity, social engagement)
- Engage social support systems
Expected recovery course
- Most trauma-exposed individuals recover without intervention; ~10% develop PTSD [2]
- With treatment, clinically meaningful improvement is expected within 8–12 weeks [2][14]
- Psychotherapy demonstrates superior long-term maintenance of gains compared to pharmacotherapy alone [16]
- Chronic PTSD is unlikely to remit without intervention [13]
References
1. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
2. Posttraumatic Stress Disorder: Evaluation and Treatment. — Sartor Z, Kelley L, Laschober R. American Family Physician. 2023.
3. Early Pharmacological Interventions for Prevention of Post-Traumatic Stress Disorder (PTSD) in Individuals Experiencing Acute Traumatic Stress Symptoms. — Bertolini F, Robertson L, Bisson JI, et al. The Cochrane Database of Systematic Reviews. 2024.
4. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (2025). — Lori A. Zoellner, Priscilla M. Schulz, Lucindra Campbell-Law, et al American Psychological Association. 2025.
5. The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. — Schnurr PP, Hamblen JL, Wolf J, et al. Annals of Internal Medicine. 2024.
6. Factors Impacting Prazosin Efficacy for Nightmares and Insomnia in PTSD Patients - A Systematic Review and Meta-Regression Analysis. — Mendes TP, Pereira BG, Coutinho ESF, et al. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025.
7. Pharmacotherapy for Posttraumatic Stress Disorder. — Seales S, Seales P. American Family Physician. 2022.
8. Posttraumatic Stress Disorder Among Adults in Communities With Mass Violence Incidents. — Moreland AD, Rancher C, Davies F, et al. JAMA Network Open. 2024.
9. Post-Traumatic Stress Disorder. — Shalev A, Liberzon I, Marmar C. The New England Journal of Medicine. 2017.
10. Early Pharmacological Interventions for Universal Prevention of Post-Traumatic Stress Disorder (PTSD). — Bertolini F, Robertson L, Bisson JI, et al. The Cochrane Database of Systematic Reviews. 2022.
11. Diagnostic accuracy of the Primary Care PTSD Screen for DSM‐5 (PC‐PTSD‐5) within a civilian primary care sample. — Williamson MLC, Stickley MM, Armstrong TW, Jackson K, Console K. Journal of Clinical Psychology. 2022.
12. Best Practices Guidelines Screening And Intervention For Mental Health Disorders And Substance Use And Misuse In The Acute Trauma Patient. — Karen J. Brasel MD MPH, Terri A. deRoon-Cassini PhD MS, Andrew Bernard MD FACS, et al American College of Surgeons (2022). 2022.
13. An Update on Psychotherapy for the Treatment of PTSD. — Rothbaum BO, Watkins LE. The American Journal of Psychiatry. 2025.
14. Pragmatic Comparative Effectiveness of Primary Care Treatments for Posttraumatic Stress Disorder. — Fortney JC, Kaysen DL, Engel CC, et al. JAMA Psychiatry. 2025.
15. An Evidence-Based Approach to Psychopharmacology for Posttraumatic Stress Disorder (PTSD) - 2022 Update. — Bajor LA, Balsara C, Osser DN. Psychiatry Research. 2022.
16. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis. — Merz J, Schwarzer G, Gerger H. JAMA Psychiatry. 2019.